Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling

Current Topics in Medicinal Chemistry

Volumn 14, Issue 23, 2014, Pages 2672-2683

  Klett, Javier ^a,b   Reeves, Jake ^a,b,c   Oberhauser, Nils ^a,b,d   Pérez Regidor, Lucía ^a,b   Martín Santamaría, Sonsoles ^a,b  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Agonist antagonist; Drug design; Modulation; Molecular modeling; Molecular recognition; Toll like receptor 4; X ray crystallography

Indexed keywords

ADJUVANT; BETA AMINO ALCOHOL DERIVATIVE; BIOLOGICAL FACTOR; CD14 ANTIGEN; COMPOUND E6020; CRX 547; DOCETAXEL; ERITORAN; ETHYL 4 OXO 4 (OXAZOLIDIN 3 YL) BUTENOATE DERIVATIVE; ETHYL PHENYL SULFAMOYLCYCLOHEXENECARBOXYLATE DERIVATIVE; HEPATITIS B VACCINE; LIPID IVA; LIPOPOLYSACCHARIDE; MISCELLANEOUS DRUGS AND AGENTS; MYELOID DIFFERENTIATION FACTOR 2; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; PHOSPHORYL LIPID A; RC 529; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTAGONIST; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE; IMMUNOLOGIC FACTOR; LY96 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN MD 2; TLR4 PROTEIN, HUMAN;

ANTIGEN STRUCTURE; ANTIGENIC MODULATION; ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; DIMERIZATION; DRUG DESIGN; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SIMULATION; X RAY CRYSTALLOGRAPHY; AGONISTS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMISTRY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; NEOPLASMS; PATHOLOGY; PROTEIN MULTIMERIZATION; SEPSIS; SYNTHESIS;

ARTHRITIS, RHEUMATOID; CRYSTALLOGRAPHY, X-RAY; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MOLECULAR DOCKING SIMULATION; NEOPLASMS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84926294788     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141215144831     Document Type: Article

References (84)

1. [1] Monie, T.P.; Bryant, C.E.; Gay, N.J. Activating immunity: lessons from the TLRs and NLRs. Trends. Biochem. Sci., 2009, 34(11), 553-561.
2. [2] Rakoff-Nahoum, S.; Medzhitov, R. Toll-like receptors and cancer. Nat. Rev. Cancer. 2009, 9(1), 57-63.
3. The Official Website of the Nobel Prize. www.nobelprize.org/nobel_prizes/medicine/laureates/2011/ (Accessed Feb, 18, 2014).
4. [4] Hennessy, E.J.; Parker, A.E.; O'Neill, A.J. Targeting of Toll-like receptors: Emerging therapeutics? Nature Rev. Drug Discov., 2010, 9(4), 293-307.
5. [5] Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol., 2004, 4(7), 499-511.
6. [6] Janeway, C.A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol., 1989, 54, 1-13.
7. [7] Lemaitre, B.; Nicolas, E.; Michaut, L.; Reichhart, J.M.; Hoffmann, J.A. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell., 1996, 86, 973-983.
8. [8] Medzhitov, R.; Preston-Hurlburt, P.; Janeway, C.A. Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature, 1997, 388(6640), 394-397.
9. [9] Schaefer, L. Extracellular matrix molecules: endogenous danger signals as new drug targets in kidney diseases. Curr. Opin. Pharmacol., 2009, 10, 185-190.
10. (a) Gill, R.; Tsung, A.; Billiar, T. Linking oxidative stress to inflammation: Toll-like receptors. Free. Radic. Biol. Med., 2010, 48, 1121-1132
11. (b) Yang, H.; Hreggvidsdottir, H.S.; Palmblad, K.; Wang, H.; Ochani, M.; Li, J.; Lu, B.; Chavan, S.; Rosas-Ballina, M.; Al-Abed, Y.; Akira, S.; Bierhaus, A.; Erlandsson-Harris, H.; Andersson, U.; Tracey, K.J. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A., 2010, 107(26), 11942-11947.
12. [11] Stewart, C.R.; Stuart, L.M.; Wilkinson, K.; van Gils, J.M.; Deng, J.; Halle, A.; Rayner, K.J.; Boyer, L.; Zhong, R.; Frazier, W.A.; Lacy-Hulbert, A.; El Khoury, J.; Golenbock, D.T.; Moore, K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11(2),155–161.
13. (a) O’Neill, L.A.; Bryant, C.E.; Doyle, S.L. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev., 2009, 61(2), 177–197.
14. (b) Kanzler, H.; Barrat, F.J.; Hessel, E.M.; Coffman, R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med., 2007, 13(5), 552–559.
15. (c) Makkouk, A.; Abdelnoor, A.M. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents. Immunopharmacol. Immunotoxicol. 2009, 31(3), 331–338.
16. (d) Casella, C.R.; Mitchell, T.C. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life. Sci., 2008, 65(20), 3231–3240.
17. (a) West, A.P.; Koblansky, A.A.; Ghosh, S. Recognition and signaling by toll-like receptors. Annu. Rev. Cell. Dev. Biol., 2006, 22, 409–437.
18. (b) Kaisho, T.; Akira S. Toll-like receptor function and signaling. J. Allergy. Clin. Immunol., 2006, 117(5), 979.
19. (c) Iwasaki, A.; Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol., 2004, 5(10), 987-995.
20. (d) Gay, N.J.; Gangloff, M. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem., 2007, 76, 141-165.
21. [14] Matsushima, N.; Tanaka, T.; Enkhbayar, P.; Mikami, T.; Taga, M.; Yamada, K.; Kuroki, Y. Comparative sequence analysis of leucinerich repeats (LRRs) within vertebrate toll-like receptors. BMC. Genomics, 2007, 8, 124.
22. (a) Kajava, A.V. Structural diversity of leucine-rich repeat proteins. J. Mol. Biol., 1998, 277(3), 519–52.
23. (b) Kobe, B.; Kajava, A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol., 2001, 11(6), 725–732.
24. [16] O’Neill, L.A.; Bowie, A.G. The family of five: TIR-domaincontaining adaptors in Toll-like receptor signalling. Nat. Rev. Immunol., 2007, 7(5), 353–364.
25. [17] Iwasaki, A.; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science, 2010, 327(5963), 291–295.
26. [18] Botos, I.; Segal, D.M.; Davies, D.R. The structural biology of Tolllike receptors. Structure, 2011, 19(4), 447-459.
27. (a) Poltorak, A.; He, X.; Smirnova, I.; Liu, M.Y.; Van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C.; Freudenberg, M.; Ricciardi-Castagnoli, P.; Layton, B.; Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science, 1998, 282(5396), 2085-2088.
28. (b) Hold, G.E.; Bryant, C.E. In: Bacterial Lipopolysaccharides. Structure, Chemical Synthesis, Biogenesis and Interaction with Host Cell; Knirel, Y.A.; Valvano, M.A. Eds.; Springer-Verlag: Wien, 2011; Chapter 12, pp. 371-387.
29. (c) Peri, F.; Piazza, M.; Calabrese, V.; Cighetti, R. In: Bacterial Lipopolysaccharides. Structure, Chemical Synthesis, Biogenesis and Interaction with Host Cell; Knirel, Y.A.; Valvano, M.A. Eds.; Springer-Verlag: Wien, 2011; Chapter 13, pp. 389-415.
30. [20] Mancek-Keber, M.; Gradisar, H.; Iñigo Pestaña, M.; Martinez de Tejada, G.; Jerala, R. Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J. Biol. Chem., 2009, 284(29), 19493-19500.
31. [21] Gioannini, T.L.; Teghanemt, A.; Zhang, D.; Coussens, N.P.; Dockstader, W.; Ramaswamy, S.; Weiss, J.P. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 4186-4191.
32. (a) Li, M.; Zhou, Y.; Feng, G.; Su, S.B. The critical role of Tolllike receptor signaling pathways in the induction and progression of autoimmune diseases. Curr. Mol. Med., 2009, 9(3), 365-74.
33. (b) Jialal, I.; Kaur, H.; Devaraj, S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J. Clin. Endocrinol. Metab., 2014, 99(1), 39-48.
34. (a) Baxevanis, C.N.; Voutsas, I.F.; Tsitsilonis, O.E. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving antic ancer vaccination strategies. Immunotherapy, 2013, 5(5), 497-511.
35. (b) Garçon, N.; Chomez, P.; Van Mechelen, M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives 1. Expert. Rev. Vaccines, 2007, 6(5), 723-739.
36. Casella, C.R.; Mitchell, T.C. Inefficient TLR4/MD-2 Heterotetramerization by Monophosphoryl Lipid A. PLoS. One, 2013, 8(4).
37. [25] Thoelen, S.; De Clercq, N.; Tornieporth, N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine, 2001, 19(17-19), 2400–2403.
38. (a) Harper, D.M.; Franco, E.L.; Wheeler, C.; Ferris, D.G.; Jenkins, D.; Schuind, A.; Zahaf, T.; Innis, B.; Naud, P.; De Carvalho, N.S.; Roteli-Martins, C.M.; Teixeira, J.; Blatter, M.M.; Korn, A.P.; Quint, W.; Dubin, G.; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 2004, 364(9447), 1757–1765;
39. (b) Paavonen, J.; Jenkins, D.; Bosch, F.X.; Naud, P.; Salmerón, J.; Wheeler, C.M.; Chow, S.N.; Apter, D.L.; Kitchener, H.C.; Castellsague, X.; de Carvalho, N.S.; Skinner, S.R.; Harper, D.M.; Hedrick, J.A.; Jaisamrarn, U.; Limson, G.A.; Dionne, M.; Quint, W.; Spiessens, B.; Peeters, P.; Struyf, F.; Wieting, S.L.; Lehtinen, M.O.; Dubin, G.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 2007, 369(9580), 2161–2170.
40. (a) Mitchell, M.S.; Kan-Mitchell, J.; Kempf, R.A.; Harel, W.; Shau, H.Y.; Lind, S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer. Res., 1988, 48(20), 5883–5893;
41. (b) JA, S.; JM, U.; al, L.P.E. HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from melacine vaccine: an updated analysis of SWOG 9035. Proc. Am. Soc. Clin. Oncol., 2002, 20:340a (abstr 1359).
42. [28] Przetak, M.; Chow, J.; Cheng, H.; Rose, J.; Hawkins, L.D.; Ishizaka, S.T. Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice. Vaccine, 2003, 21(9-10), 961-970.
43. (a) Wang, S.; Astsaturov, I.A.; Bingham, C.A.; McCarthy, K.M.; von Mehren, M.; Xu, W.; Alpaugh, R.K.; Tang, Y.; Littlefield, B.A.; Hawkins, L.D.; Ishizaka ST, Weiner, L.M. Effective antibody therapy induces host protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer. Immunol. Immunother., 2012, 61(1), 49-61.
44. (b) Morefield, G.L.; Hawkins, L.D.; Ishizaka, S.T.; Kissner, T.L.; Ulrich, R.G. Synthetic Toll-Like Receptor 4 Agonist Enhances Vaccine Efficacy in an Experimental Model of Toxic Shock Syndrome. Clin. Vaccine. Immunol., 2007, 14 (11), 1499–1504.
45. [30] Stöver, A.G.; Da Silva Correia, J.; Evans, J.T.; Cluff, C.W.; Elliott, M.W.; Jeffery, E W; Johnson, D.A; Lacy, M.J; Baldridge, J.R; Probst, P; Ulevitch, R.J; Persing, D.H; Hershberg, R.M. Structure-activity relationship of synthetic toll-like receptor 4 agonists. J. Biol. Chem., 2004, 279(6), 4440-4449.
46. [31] DA, J. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr. Top. Med. Chem., 2008, 8(2), 64-79.
47. [32] Johnson, D.A.; Sowell, C.G.; Johnson, C.L.; Livesay, M.T.; Keegan, D.S.; Rhodes, M.J.; Ulrich, J.T.; Ward, J.R.; Cantrell, J.L.; Brookshire, V.G.; Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett., 1999, 9(15), 2273-2278.
48. Bowen, W.S.; Minns, L.A.; Johnson, D.A.; Mitchell, T.C.; Hutton, M.M.; Evans, J.T. Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci. Signal, 2012, 5(211), ra13.
49. [34] Chan, M.; Hayashi, T.; Mathewson, R.D.; Nour, A.; Hayashi, Y.; Yao, S.; Tawatao, R.I.; Crain, B.; Tsigelny, I.F.; Kouznetsova, V.L.; Messer, K.; Pu, M.; Corr, M.; Carson, D.A.; Cottam, H.B. Identification of Substituted Pyrimido (5,4-b)indoles as Selective Toll-Like Receptor 4 Liands, J. Med. Chem., 2013, 56(11), 4206-4223.
50. [35] Neve, J.E.; Wijesekera, H.P.; Duffy, S.; Jenkins, I.D.; Ripper, J.A.; Teague, S.J.; Campitelli, M.; Garavelas, A.; Nikolakopoulos, G.; Le, P.V.; de, A.L.P.; Pham, N.B.; Shelton, P.; Fraser, N.; Carroll, A.R.; Avery, V.M.; McCrae, C.; Williams, N.; Quinn, R.J. Euodenine A: a small-molecule agonist of human TLR4. J. Med. Chem., 2014, 57(4), 1252-1275.
51. Shanmugam, A.; Rajoria, S.; George, A.L.; Mittelman, A.; Suriano, R.; Tiwari, R.K. Synthetic Toll Like Receptor-4 (TLR4) Agonist Peptides as a Novel Class of Adjuvants. PloS. One, 2012, 7(2).
52. [37] Wittebole, X.; Castanares-Zapatero, D.; Laterre, P.F. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators. Inflamm., 2010, 10, 1155-1161.
53. [38] Shirey, K.A.; Lai, W.; Scott, A.J.; Lipsky, M.; Mistry, P.; Pletneva, L.M.; Karp, C.L.; McAlees, J.; Gioannini, T.L.; Weiss, J.; Chen, W.H.; Ernst, R.K.; Rossignol, D.P.; Gusovsky, F.; Blanco, J.C.; Vogel, S.N. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature, 2013, 497(7450), 498-502.
54. (a) Peri, F.; Marinzi, C.; Barath, M.; Granucci, F.; Urbano, M.; Nicotra, F. Synthesis and biological evaluation of novel lipid A antagonists. Bioorg. Med. Chem., 2006, 14(1), 190-9.
55. (b) Peri, F.; Granucci, F.; Costa, B.; Zanoni, I.; Marinzi, C.; Nicotra, F. Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides. Angew. Chem. Int. Ed. Engl., 2007, 46(18), 3308-12.
56. (c) Piazza, M.; Rossini, C.; Della Fiorentina, S.; Pozzi, C.; Comelli, F.; Bettoni, I.; Fusi, P.; Costa, B.; Peri, F. Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization. J. Med. Chem., 2009, 52(4), 1209-1213.
57. (a) Piazza, M.; Calabrese, V.; Damore, G.; Cighetti, R.; Gioannini, T.; Weiss, J.; Peri, F. A synthetic lipid A mimetic modulates human TLR4 activity. ChemMedChem., 2012, 7(2), 213-217.
58. (b) Cighetti, R.; Ciaramelli, C.; Sestito, S.E.; Zanoni, I.; Kubik, L.; Ardá-Freire, A.; Calabrese, V.; Granucci, F.; Jerala, R.; Martín-Santamaría, S.; Jiménez-Barbero, J.; Peri, F.; Modulation of CD14 and TLR4_MD-2 Activities by a Synthetic Lipid A Mimetic. ChemBioChem., 2014, 15(2), 250-258.
59. (a) Park, S.J.; Kang, S.H.; Kang, Y.K.; Eom, Y.B.; Koh, K.O.; Kim, D.Y.; Youn, H.S.; Inhibition of homodimerization of Tolllike receptor 4 by 4-oxo-4-(2-oxo-oxazolidin-3-yl)-but-2-enoic acid ethyl ester. Int. Immunopharmacol., 2011, 11(1), 19-22.
60. (b) Jin, G.H.; Li, H.; An, S.; Ryu, J.H.; Jeon, R. Design, synthesis and activity of benzothiazole-based inhibitors of NO production in LPSactivated macrophages. Bioorg. Med. Chem. Lett., 2010, 20(21), 6199–6202;
61. (c) Kawamoto, T.; Ii, M.; Kitazaki, T.; lizawa, Y.; Kimura, H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur. J. Pharmacol., 2008, 584(1), 40-48;
62. (d) Chavez, S.A.; Martinko, A.J.; Lau, C.; Pham, M.N.; Cheng, K.; Bevan, D.E.; Mollnes, T.E.; Yin, H. Development of β-Amino Alcohol Derivatives That Inhibit Tolllike Receptor 4 Mediated Inflammatory Response as Potential Antiseptics. J. Med. Chem., 2011, 54 (13), 4659–4669.
63. (a) Barata, T.S.; Teo, I.; Brocchini, S.; Zloh, M.; Shaunak, S. Partially glycosylated dendrimers block MD-2 and prevent TLR4-MD-2-LPS complex mediated cytokine responses. PLoS Comput. Biol., 2011, 7(6), e1002095.
64. (b) Barata, T.; Teo, I.; Lalwani, S.; Simanek, E.; Zloh, M.; Shaunak, S. Computational design principles for bioactive dendrimer based constructs as antagonists of the TLR4-MD-2-LPS complex. Biomaterials, 2011, 32(33):8702-8711.
65. (a) Jin, M.S.; Kim, S.E.; Heo, J.Y.; Lee, M.E.; Kim, H.M.; Paik, S.G.; Lee, H.; Lee, J.O. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell, 2007, 130(6), 1071–1082.
66. (b) Liu, L.; Botos, I.; Wang, Y.; Leonard, J.N.; Shiloach, J.; Segal, D.M.; Davies, D.R. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science, 2008, 320(5874), 379–381.
67. [44] Park, B.S.; Song, D.H.; Kim, H.M.; Choi, B.S.; Lee, H.; Lee, J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature, 2009, 458(7242), 1191–1195.
68. [45] Park, B.S.; Lee, J.O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med., 2013, 45, e66.
69. [46] Ohto, U.; Fukase, K.; Miyake, K.; Shimizu, T. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(19), 7421-7426.
70. [47] Ohto, U.; Yamakawa, N.; Akashi-Takamura, S.; Miyake, K.; Shimizu, T. Structural analyses of human Toll-like receptor 4 polymorphisms D299G and T399I. J. Biol. Chem., 2012, 287(48), 40611-40617.
71. [48] Kim, H.M.; Park, B.S.; Kim, J.I.; Kim, S.E.; Lee, J.; Oh, S.C.; Enkhbayar, P.; Matsushima, N.; Lee, H.; Yoo, O.J.; Lee, J.O. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell, 2007, 130(5), 906-917.
72. [49] Han, J.; Kim, H.J.; Lee, S.C.; Hong, S.; Park, K.; Jeon, Y.H.; Kim, D.; Cheong, H.K.; Kim, H.S. Structure-based rational design of a Toll-like receptor 4 (TLR4) decoy receptor with high binding affinity for a target protein. PLoS. One, 2012, 7(2), e30929.
73. [50] Ohto, U.; Fukase, K.; Miyake, K.; Satow, Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science, 2007, 316(5831), 1632-1634.
74. RCSB Protein Data Bank. www.rcsb.org (Accessed Feb, 18, 2014).
75. [52] Yu, L.; Phillips, R.L.; Zhang, D.; Teghanemt, A.; Weiss, J.P.; Gioannini, T.L. NMR studies of hexaacylated endotoxin bound to wild-type and F126A mutant MD-2 and MD-2·TLR4 ectodomain complexes. J. Biol. Chem., 2012, 287(20), 16346-16355.
76. [53] As an example: Lindert, S.; Kekenes-Huskey, P.M.; McCammon, J.A. Long-timescale molecular dynamics simulations elucidate the dynamics and kinetics of exposure of the hydrophobic patch in troponin C. Biophys J., 2012, 103(8), 1784-1789.
77. [54] Basith, S.; Manavalan, B.; Govindaraj, R.G.; Choi, S. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L. PLoS. One, 2011, 6(8), e23989.
78. [55] Garate, J.A.; Oostenbrink, C. Lipid A from lipopolysaccharide recognition: structure, dynamics and cooperativity by molecular dynamics simulations. Proteins, 2013, 81(4), 658-674.
79. [56] DeMarco M.L.; Woods R.J. From agonist to antagonist: structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins. Mol. Immunol., 2011, 49(1-2), 124-133.
80. [57] Paramo, T.; Piggot, T.J.; Bryant, C.E.; Bond, P.J. The Structural Basis for Endotoxin-induced Allosteric Regulation of the Toll-like Receptor 4 (TLR4) Innate Immune Receptor, J. Biol. Chem., 2013, 288(51), 36215-36225.
81. [58] Resman, N.; Gradisar, H.; Vasl, J.; Keber, M.M.; Pristovsek, P.; Jerala, R. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS. Lett., 2008, 582(28), 929-934.
82. [59] Koo, J.E.; Park, Z.Y.; Kim, N.D.; Lee, J.Y. Sulforaphane inhibits the engagement of LPS with TLR4/MD2 complex by preferential binding to Cys133 in MD2. Biochem. Biophys. Res. Commun., 2013, 434, 600-605.
83. [60] Neal, M.D.; Jia, H.; Eyer, B.; Good, M.; Guerriero, C.J.; Sodhi, C.P.; Afrazi, A.; Prindel, T. Jr.; Ma, C.; Branca, M.; Ozolek, J.; Brodsky, J.L.; Wipf, P.; Hackam, D.J. Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) Inhibitors. PloS One, 2013. 8(6), e65779.
84. Tanimoto, T. An Elementary Mathematical stheory of Classification and Prediction. Inter. IBM Tech. Rep., 1957 (8).